Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Carfilzomib Intravenous Powder (generic for Kyprolis®).
| BERLIN, Conn., June 16, 2021 /PRNewswire/ --Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Carfilzomib Intravenous Powder (generic for Kyprolis®). This product was developed in collaboration with Natco Pharma Limited. Breckenridge received final approval for the 10mg and 60mg strengths and tentative approval for the 30mg strength. Onyx Therapeutics, Inc., Breckenridge and Natco have reached a Settlement Agreement and the District Court case against Breckenridge and Natco has been dismissed. By virtue of the settlement, Breckenridge has been granted a license permitting the launch of its generic carfilzomib product on a date that is held as confidential in 2027 or sooner depending on certain occurrences. The parties cannot make further comment as to the terms of the Settlement Agreement. According to industry sales data, Kyprolis generated annual sales of $711 million during the twelve months ending April 2021.
About Breckenridge: About Natco: For further information, please contact: *All brand names and trademarks are the property of their respective owners.
SOURCE Breckenridge Pharmaceutical, Inc. |
View original content to download multimedia:
